Blue Moon Metals refutes short-seller claims on Nussir project (BMM:NASDAQ)
Blue Moon Metals denied allegations made by short seller Viceroy Research, alleging a "short-and-distort" campaign containing "numerous false, unfounded and meritless statements."
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Blue Moon Metals denied allegations made by short seller Viceroy Research, alleging a "short-and-distort" campaign containing "numerous false, unfounded and meritless statements."
Blue Moon Metals refutes short-seller claims on Nussir project (BMM:NASDAQ) | Seeking Alpha
Ployker/iStock via Getty Images
Blue Moon Metals (
BMM
) down 4.3% in Thursday's trading after it
denied
allegations made by short seller Viceroy Research, alleging a "short-and-distort" campaign containing "numerous false, unfounded, and meritless statements" about the company.
Blue Moon (
BMM
) said all
permits for
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
enCore Energy GAAP EPS of -$0.21 misses by $0.07, revenue of $15.7M beats by $2.39M
enCore Energy press release (EU:CA): Q2 GAAP EPS of -$0.21 misses by $0.07. Revenue of $15.7M beats by $2.39M.
Mandatum Oyj Non-GAAP EPS of â¬0.13, revenue of â¬22.4M
Mandatum Oyj Q2 results: non-GAAP EPS â¬0.13, revenue â¬22.4M flat Y/Y, profit before taxes jumps to â¬79.1M on net finance gainsâread now.
Connect Biopharma Holdings Limited Non-GAAP EPS of -$0.27 misses by $0.04, revenue of $2.77M beats by $1.9M
Connect Biopharma (CNTB) Q2 update: Non-GAAP EPS miss, revenue surge to $2.77M, R&D-driven loss and 1+ year cash runway.
Paragon Technologies GAAP EPS Turns Positive at $0.05, Revenue Beats at $33.3M
Paragon Technologies reports a strong quarter with GAAP EPS of $0.05 and revenue of $33.3 million, beating expectations. Improved gross margins and cost controls drive profitability, with optimistic guidance ahead.
